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Abstract
Background Recent changes in the understanding and management of multiple sclerosis (MS) have increased the role of MRI 
in supporting diagnosis and disease monitoring. However, published guidelines on the use of MRI in MS do not translate 
easily into different clinical settings and considerable variation in practice remains. Here, informed by published guidelines 
for the use of MRI in MS, we identified a clinically informative MRI protocol applicable in a variety of clinical settings, 
from district general hospitals to tertiary centres.
Methods MS specialists geographically representing the UK National Health Service and with expertise in MRI examined 
existing guidelines on the use of MRI in MS and identification of challenges in their applications in various clinical settings 
informed the formulation of a feasible MRI protocol.
Results We identified a minimum set of MRI information, based on clinical relevance, as well as on applicability to various 
clinical settings. This informed the selection of MRI acquisitions for scanning protocols, differentiated on the basis of their 
purpose and stage of the disease, and indication of timing for scans. Advice on standardisation of MRI requests and report-
ing, and proposed timing and frequency of MRI scans were generated.
Conclusions The proposed MRI protocol can adapt to a range of clinical settings, aiding the impetus towards standardisa-
tion of practice and offering an example of research-informed service improvement to support optimisation of resources. 
Other neurological conditions, where a gap still exists between published guidelines and their clinical implementation, may 
benefit from this same approach.
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Introduction
Magnetic resonance imaging (MRI) is routinely used in clin-
ical practice to detect and monitor inflammatory lesions in 
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as well as disease-modifying treatments (DMTs), have more 
recently increased the demand for MRI scans to allow early 
diagnosis and monitoring of treatment safety and efficacy [2, 
3]. This has increased the burden on equipment and health-
care professionals, requiring rationalisation of resources.
Published guidelines on the use of MRI in MS exist [4, 
5]. While these guidelines provide comprehensive recom-
mendations, they do not translate easily into different clinical 
settings and considerable variation in practice remains [6–8]. 
Indeed, wide variations exist in the MRI acquisition proto-
cols and timing of scanning, as well as in the reporting of 
images [9]. This makes within-patient, as well as between-
centre comparisons difficult, delaying diagnosis and affect-
ing treatment decisions. This variability underlines the need 
for further direction on the implementation of published 
guidelines to harmonise practice through the development 
of standardised MRI protocols and reports in MS that are 
informative, yet feasible and adaptable to a range of clinical 
settings within the National Health Service (NHS).
Here we report the outcome of a workshop that brought 
together MS specialists geographically representing the UK 
NHS and with expertise in MRI and that identified clinically 
informative MRI protocols applicable in a variety of clinical 
settings, from district general hospitals to tertiary centres.
Methods
The authors of this manuscript are MS specialists geographi-
cally representing the UK NHS and with expertise in MRI, 
either as neurologists with academic interest in neuroimag-
ing or as neuroradiologists with MS as a specialist interest. 
They work as clinical academics and/or as NHS consult-
ants in specialised MS centres, as well as in district general 
hospitals (DGH). Prior to the authors’ meeting to plan the 
present work, a comprehensive literature review and exami-
nation of MRI protocols was conducted to identify the points 
that made implementation of the existing guidelines chal-
lenging in the clinical practice across NHS settings. The 
authors completed a pre-meeting questionnaire to gather 
information on their experience with MRI protocols in NHS 
centres and to inform the scope for improvement. Both lit-
erature review and the outcome of the questionnaires were 
discussed in detail during the meeting to assess the need for 
a standardised MRI protocol applicable across clinical set-
tings and to evaluate between-centre differences that could 
inform the development of minimum recommended MRI 
protocol for MS.
Table 1  Indications for MRI in MS
Clinical situation Indication for MRI Clinical gain
Suspected MS To identify findings suggestive of neuroinflammation MRI fulfilment of diagnostic criteria
Newly diagnosed MS
To assess short/medium-term risks of MS activity
To characterise the type and extent of MS damage
Decision about DMTs initiation
MS monitoring with* or without DMTs
To detect MRI activity
*To characterise the type of damage
Guidance on DMT selection 
Assessment of response to DMTs 
*Assessment of safety of DMTs
Suspected relapse or disability worsening To detect change in lesion burden or activity Assessment of ongoing inflammatory activity
The indication for MRI scanning in MS ranges from diagnosis to disease or DMTs monitoring, as highlighted below. MRI supports diagnosis, as 
well as disease monitoring. When a relapse cannot be confirmed purely on clinical grounds, MRI scan can be used to confirm clinical suspicion. 
Monitoring during DMTs aims to detect disease activity, as well as to characterise the type of damage that appears on the scan to exclude oppor-
tunistic infections such as PML
The asterisk indicates that MRI monitoring in patients on DMT is relevant to characterise the type of damage, as well as to assess safety of DMT
DMT disease-modifying treatment, JVC John Cunningham virus, MRI magnetic resonance imaging, MS multiple sclerosis, PML progressive 
multifocal leukoencephalopathy
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Results
Timing of MRI scans for MS diagnosis 
and monitoring
The clinical indications for MRI in MS vary from diagnosis 
to monitoring, as well as from assessment of treatment effi-
cacy to surveillance for opportunistic infections (Table 1). 
An overview of the suggested timing for MRI scans in the 
diagnosis and monitoring of MS patients is reported for a 
period of 5 years in Fig. 1. This period is crucial for its long-
term diagnostic and a prognostic value [10]. 
Diagnosis
When the suspicion of clinically isolated syndrome (CIS) or 
of MS is raised, both brain and spinal cord scans should be 
requested [2, 11]. As well as providing information regard-
ing lesion dissemination in space, spinal cord MRI is also 
valuable for differential diagnosis, when uncertainty exists 
over the nature of brain lesions [12, 13]. Although currently 
not routinely performed, MRI scanning of the optic nerve is 
important in patients who present with symptoms of visual 
dysfunction to aid the diagnostic process [2].
The administration of a gadolinium-based contrast agent 
(Gd) is important in the diagnostic workup to demonstrate 
dissemination in time of lesions. Therefore, it should be 
included in the diagnostic MRI protocol, when clinical sus-
picion of CIS or MS has been raised [2]. Gd highlights focal 
inflammatory activity during the preceding weeks (typically 
6–8 weeks) and thus aids earlier diagnosis. Post-contrast 
MRI scan is also useful for the purpose of differential diag-
nosis [14]. Figure 2 offers indications of a minimum set of 
clinically informative MRI acquisitions that could be consid-
ered in a MRI protocol for MS diagnosis. Other sequences, 
e.g. 3D-T2*echo-planar imaging (EPI) for central vein sign, 
double inversion recovery (DIR) for cortical lesions, phase-
sensitive inversion-recovery (PSIR) for improved detection 
of spinal cord lesions and MR spectroscopy for atypically 
looking MS lesions (e.g., tumefactive lesions), may be also 
Fig. 1  Timing of MRI scans in the diagnosis and monitoring of MS 
patients. The authors advised to perform a brain and spinal cord scan 
at diagnosis. After the beginning of DMT or after a change in DMT, 
brain MRI scan was indicated yearly for at least 5 years, with a re-
baseline brain scan 4–6  months after initiating or changing DMT. 
This was to interpret more confidently response to treatment at an 
early stage of the disease. More frequent scans were left at the discre-
tion of the clinician, based on individual cases. Spinal cord MRI scan 
was advised every 2 years for at least 5 years after initiation or change 
of DMT, even in the absence of clear spinal cord signs or symptoms, 
with more frequent scans left at the discretion of the clinician, based 
on individual cases. In patients with predominant involvement of the 
spinal cord, yearly spinal scans may be more appropriate. The initial 
assessments should be conducted with the use of contrast; subsequent 
MRI scans for monitoring of disease activity, as well as of DMT effi-
cacy, may include contrast when clinically indicated. The proposed 
timing assumes the start of DMTs soon after diagnosis. When this 
is not possible or indicated, monitoring would be left at the discre-
tion of the clinician, but advised to be regular. CIS clinically isolated 
syndrome, MS multiple sclerosis, DMT disease-modifying treatment, 
MRI magnetic resonance imaging
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considered in addition, if possible and necessary. These 
sequences are more frequently adopted in specialist centres 
because they require longer acquisition time and physics 
expertise for standardisation.
Detection of disease activity and monitoring of efficacy
Monitoring MRI scans are useful in naïve patients, as well as 
at the beginning or following initiation or change of DMTs, 
or if a relapse is suspected, but cannot be confirmed purely 
on clinical grounds. Indeed, the importance of MRI to con-
firm stability is highlighted by the role of radiological activ-
ity in the evaluation of treatment response [1, 15].
Spinal cord MRI can reveal asymptomatic disease activ-
ity, as well as predict disease evolution [16]. Therefore, the 
authors felt that it should be performed regularly in addi-
tion to the brain scans, especially, but not exclusively, in 
patients in whom a previous involvement of the spinal cord 
has been demonstrated clinically or radiologically. Indeed, 
about 58% of new spinal cord lesions can be asymptomatic 
and 25% of patients with relapsing MS develops at least 
one asymptomatic spinal cord lesion over 1.5 years [11]; 
when only patients with stable RRMS are considered, 10% 
of them show subclinical spinal cord lesion activity alone 
[11]. Asymptomatic spinal cord lesions can also predict 
relapses, when combined with asymptomatic brain lesions 
[11]. Therefore, as spinal cord MRI can disclose subclini-
cal disease activity in otherwise clinically stable MS, the 
authors supported its routine use in patient’s monitoring 
throughout the course of the disease and regardless of the 
clinical manifestation of MS in the cord.
Gd should be considered to aid detection of new inflam-
matory activity, when this would be too difficult to detect, 
due to high lesion burden, as well as for its prognostic utility, 
e.g., brain ring-enhancement patterns may forebode irrevers-
ible tissue damage and thus brain volume loss [17]. In the 
post-partum period, when monitoring is particularly impor-
tant because of higher risk of relapse [18], the use of contrast 
enhancement may be limited by breastfeeding.
When patients are on specific DMTs, the primary purpose 
of a follow-up MRI scan is the detection of new inflamma-
tory activity and the exclusion of opportunistic infections for 
safety of DMT prescription. As DMTs may reach their peak 
level of activity on MRI months after their initiation [19], 
a re-baseline scan beyond this time point is advisable. The 
authors felt that whether this scan should be performed with 
or without contrast enhancement should depend on clinical 
considerations such as the level of inflammatory activity at 
DMT initiation [20], the type of medication started [21] and 
the age of the patient [22] that all together define a risk for 
active disease. The presence or persistence of a Gd-active 
MRI scan at re-baseline could predict subsequent clinical 
Fig. 2  Suggested MRI acquisitions for MS diagnosis and monitor-
ing. 3D acquisitions should be preferred as they make head position-
ing less critical, since readers can electronically re-slice the acquired 
image. DIS dissemination in space, DIT dissemination in time, MRI 
magnetic resonance imaging, MS multiple sclerosis, CIS clinically 
isolated syndrome, 2D 2 dimensional, 3D 3 dimensional, T1WI 
T1-weighted imaging, T2WI T2-weighted imaging, FLAIR fluid-
attenuated inversion recovery, STIR short-TI inversion recovery, DWI 
diffusion-weighted imaging, SWI susceptibility-weighted imaging, 
GRE gradient recalled echo, FSE fast spin echo
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and MRI activity [20, 23] and thus could indicate a subgroup 
of patients at higher risk of activity during DMTs.
The most recent classification of disease courses places 
importance on the presence or absence of disease activity 
also in the progressive forms of MS [24]. Also, with DMTs 
licenced in these stage (secondary progressive) or form (pri-
mary progressive) of the disease to control active inflamma-
tion, the authors felt that an approach to monitoring similar 
to the one used for relapsing MS would be reasonable, at 
least in the first few years (Fig. 1). MRI in progressive MS is 
a field in evolution that is likely to benefit from the introduc-
tion of methods to measure brain or cord atrophy in clinical 
practice [25].
Monitoring of DMTs safety
Patients treated with natalizumab or exposed to prolonged 
periods of lymphopenia with other DMTs may be at greater 
risk of progressive multifocal leukoencephalopathy (PML) 
[26]. Patients at risk of PML are typically those with anti-
John Cunningham virus (JCV) antibodies, who have had 
treatment with natalizumab for over 18 months and have 
been given immunosuppressants before receiving natali-
zumab [27]. There is evidence to suggest that the manage-
ment of PML is more successful if the condition is detected 
in a pre-symptomatic state through MRI [28]. Therefore, 
the differential diagnosis of new lesions is key: any lesions 
identified after initiating therapy with natalizumab, espe-
cially if more than 18 months, should be treated with sus-
picion. Any MRI changes consistent with PML that occur 
in immunocompromised patients should be classified as 
“radiologically-suspected PML” [29]. An algorithm has 
been developed to guide the use of MRI to monitor patients 
treated with natalizumab, based on anti-JCV antibody status 
and index value [29].
MRI acquisition
The detailed definition of a standardised MRI acquisi-
tion protocol was beyond the scope of this work, as the 
authors felt that such protocol for implementation of MRI 
sequences in the NHS would be more appropriately defined 
and endorsed by relevant professional bodies. However, the 
authors identified some characteristics of the MRI acquisi-
tion protocol that would be informative and feasible in any 
clinical setting.
Scanner strength
Different clinical MRI scanners may use different magnetic 
fields of strength, with higher strengths yielding greater res-
olution. Thus, when scanning individual patients, changes in 
scanner strength may generate an inaccurate representation 
of disease evolution over time, over- or under-estimating MS 
lesions. Previous scanner strength should be a primary con-
sideration when deciding about future MRI scans to ensure 
comparability between studies. When moving to a different 
scanner strength, especially from lower to higher, re-baseline 
scan is advisable. A minimum magnet strength of 1.5T (T) 
is important to preserve an adequate level of detail in the 
images and facilitate reproducibility between centres.
Sequences
MRI scanning requirements may differ from diagnosis to 
monitoring (Fig. 2), as well as from assessment of effi-
cacy to surveillance of opportunistic infections. Among 
the MRI sequences typically helpful to detect MS lesions, 
some may be of particular help to gain insight into specific 
aspects of MS pathology, such as perivenular infiltration, 
cortical damage and tissue loss. Susceptibility weighted 
imaging (SWI) at diagnosis can demonstrate the perivenu-
lar orientation of lesions, which is helpful to distinguish 
between MS and ischemic lesions [30]. 3D-fluid attenuated 
inversion recovery (FLAIR) sequence is useful in diagno-
sis and monitoring of MS due to its ability to increase 
lesion’s visibility, as well as to detect cortical lesions [31]. 
The improved detection of posterior fossa lesions with 3D 
FLAIR might also obviate the need for axial T2 sequences 
[31]. 3D-T1 acquisition is useful for assessing changes in 
brain volume over time. While currently this parameter 
is likely to be qualitative in most of the reports, it may 
Fig. 3  Head position during MRI acquisition. The anterior commis-
sure–posterior commissure (AC–PC) line should be used to align 
head position to allow scan comparison, when only 2D acquisitions 
are possible. This line is typically ~ 9° steeper than the orbito-meatal 
line, traditionally used in computerised tomography (CT) scans. MRI 
magnetic resonance imaging, 2D 2 dimensional
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become quantitative, as the use of automated segmentation 
software becomes more widespread [32].
Head position
3D acquisitions mitigate the variability introduced by 
changes in head position by enabling readers to electroni-
cally re-slice the acquired image. However, this is not pos-
sible on all picture archiving and communication systems 
(PACS). Therefore, in this eventuality and, more impor-
tantly, for serial MRI scans using 2D acquisitions, the 
position of the patient within the magnet bore is important 
for between-study comparison. Differences in head posi-
tion between scans can significantly change the orientation 
of axial images, making comparisons difficult. The use of 
the anterior commissure–posterior commissure (AC–PC) 
line, defined as the line passing through the superior edge 
of the AC and the inferior edge of the PC, for aligning 
head position remains recommended [33] (Fig. 3).
Use of contrast agent
Gd is frequently used for its ability to highlight regions of 
altered blood–brain barrier and thus areas of active inflam-
mation, thereby providing an indicator of current disease 
activity and a means to assess DMTs efficacy and safety in 
PML surveillance [1, 34]. However, evidence suggests a 
retention of Gd in the body, following a scan [35]. There-
fore, the Gd for routine MRI scans should be used when 
necessary, with specific macrocyclic Gd agents being rec-
ommended over linear agents for safety reasons [36, 37]. 
Since Gd may be used both at diagnosis and during DMTs 
or natural history monitoring, the authors felt that, in line 
with published recommendation, Gd should be used only 
when deemed to be clinically necessary: (1) at diagnosis, 
(2) in cases of high lesion burden to identify new lesions, 
(3) to confirm the clinical suspicion of disease activity 
(e.g., worsening in disability, for which a relapse is sus-
pected, but no clear episode is identifiable), and (4) where 
it may critically inform treatment decisions (e.g., assess-
ment of treatment efficacy [21] or safety [38]).
MRI scan requests and reports
With an increasing number of scans being performed for 
MS diagnosis and management, there is further need to 
streamline scan requests and reports. Table 2 reports the 
proposed essential components of request forms and post-
scan reports identified by the authors. Reports should be pre-
pared with sufficient detail to stand alone, should the MRI 
images be unavailable. The use of the term “progression” on 
Table 2  MRI request forms and post-scan reports
Diagnosis
Request form Post-scan report
Hypothesised localisation of signs/symptoms
Duration of symptoms




MRI sequences and use of contrast
Scan yielding results suggestive of inflammatory demyelination:
No Yes
Other possible diagnoses Fulfilment of DIS/DIT criteria 
T2-hyperintense/post contrast T1 hyperintense and 
T1-hypointense lesion count
Subjective assessment of brain/cord volume loss, 
comment on lesion size and distribution
Monitoring
Request form Post-scan report
Clinical confirmation of MS
Clinical changes from previous scan
Presence/absence of DMTs
Specific query, e.g. new or active lesions, signs of 
PML
Date and details of previous scan for comparative purposes
Imaged body part
Magnet strength
MRI sequences and use of contrast
Radiological confirmation of MS
T2-hyperintense/post contrast T1 hyperintense and T1-hypointense lesion count
PML report
Subjective assessment of brain/cord volume loss
The authors suggested that the clinician provides the neuroradiologist with relevant information about the individual patient and his history 
(left). The post-scan reports should contain information that would allow interpretability of the results (right)
DIT duration in time, DIS duration in space, MS multiple sclerosis, PML progressive multifocal leukoencephalopathy, DMTs disease-modifying 
treatments, MRI magnetic resonance imaging
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radiological reports was felt by the authors to be inaccurate 
and thus to be discouraged, with “evidence of radiologi-
cally active disease” or “radiological evolution” proposed 
as alternative terminology.
MS lesion count
Whenever possible, absolute lesion counts should be 
reported, i.e., information about the number of T2-hyper-
intense, T1-hypointense and T1-hyperintense lesions in the 
post-contrast T1-weighted scans. This is relevant for both 
diagnostic, as well as monitoring scans [1]. Where there 
is high lesion load, especially if lesions are confluent, the 
authors felt that, although not ideal, a categorical approach 
to the number of T2-hyperintense lesions would be accept-
able (e.g., less than 9 T2-hyperintense lesions, between 10 
and 20 hyperintense lesions etc.). For monitoring scans, the 
detection of new lesions and/or changes in the size of pre-
existing lesions should be indicated. Lesion number should 
be indicated separately for the brain and the spinal cord. 
Indication of lesion location should be given to support the 
diagnostic process, as well as to provide clinically meaning-
ful indications on the current or future patients’ disability 
[39].
Brain and spinal cord volume
Comments on brain or spinal cord volumes should be pro-
vided in the report, at least as qualitative evaluation of the 
presence of MS-related tissue loss, by comparing the last 
scan with what expected in the normal, age-matched popula-
tion, or as an assessment of the rate of volume reduction over 
time, by comparing the last scan with the first (or the most 
meaningful) available scan for the same patient.
Conclusions
In this report, we address the need for a standardisation of 
practice in the use of MRI for MS across clinical settings 
within the NHS. We suggest MRI scanning protocols and 
templates for MRI requests and post-scan reports in the 
attempt to facilitate diagnosis and optimise management of 
patients with MS, while considering the heterogeneity of 
resources and expertise that different clinical settings may 
present. The role of optic nerve imaging in MS was not 
discussed, as this is not currently included in the imaging 
diagnostic criteria for MS and, in MS monitoring, its infor-
mativeness is established by the clinician in each individual 
case [2].
Our proposed protocol aims to strike a balance between 
the need for frequent and accurate radiological information 
and the availability of equipment and staffing resources. The 
timing of MRI scans aims to capture, as early as possible, 
MS or its evolution that can be amenable to the starting 
or the changing of DMTs. The MRI acquisition protocol 
proposes a minimum, standardised set of meaningful infor-
mation that can be used to manage MS. Indeed, published 
international guidelines offer guidance on MRI features that 
are most relevant to the diagnosis of MS [4]. Their imple-
mentation in clinical practice, however, has proven to be 
challenging across clinical settings, especially when the care 
of MS patients is outside specialist centres. Our proposed 
application of MRI for MS in clinical practice balances the 
specialist requirements with practical limitations imposed 
by limited resources by streamlining acquisition protocols 
and by standardising the timing of scans to integrate MRI 
findings in the clinical decision-making process. This effort 
can aid the impetus towards standardisation of practice and 
offer an example of research-informed service improvement 
to support optimisation of resources.
The authors also tackled the issue of effective communi-
cation between specialists, i.e., clinicians and radiologists, 
that is paramount in a multi-disciplinary context. We tailored 
our suggestions regarding the format of requests and reports 
for MRI scanning so that they can be used as a standardised, 
time-sparing tool for obtaining clinically relevant MRI infor-
mation about MS patients. Indeed, the authors felt that clear, 
minimal information about the reason for the MRI scan was 
essential for the radiologist to correctly address the clini-
cian’s question. Similarly, quantitative information about the 
MRI scan was felt to be necessary to manage MS effectively 
and promptly by clinicians. This quantitative, rather than 
merely descriptive, approach to MRI scan reporting for diag-
nostic, as well as for MRI monitoring scans, can contribute 
to an improved integration of MRI information in the clini-
cal management of patients.
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